Download PDF
Semin Thromb Hemost 2002; 28(4): 369-378
DOI: 10.1055/s-2002-34306
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Pharmacokinetic and Pharmacodynamic Characterization of a Medium-Molecular-Weight Heparin in Comparison with UFH and LMWH

Susanne Alban1 , Dieter Welzel1 , H. Coenraad Hemker2
  • 1Institute of Pharmacy, University of Regensburg, Regensburg, Germany and
  • 2Department of Biochemistry and Synapse BV, Cardiovascular Research Institute (CARIM), Maastricht, The Netherlands
Further Information

Publication History

Publication Date:
23 September 2002 (online)

    Permissions and Reprints

ABSTRACT

Despite the well-established medical use of heparins, the question arises whether the efficacy-safety ratio of the available heparins can still be improved. Therefore, a medium-molecular-weight heparin (MMWH), a new heparin with an average molecular weight of 10.5 kDa and a narrow molecular weight range (9.5 to 11.5 kDa) was developed. Its in vitro activities amount to 174.9 anti-factor Xa (aXa) U/mg and 170.0 antithrombin (aIIa) U/mg. In the presented randomized, double-blind, cross-over study in healthy volunteers, the pharmacokinetics and pharmacodynamics of MMWH are compared with those of an unfractionated heparin (UFH) and a low-molecular-weight heparin (LWMH; enoxaparin). After subcutaneous administration of 9000 aXa-U of either heparin in 16 volunteers, the prolongation of the activated partial thromboplastin time (aPTT), the aXa activity, and the aIIa activities were determined at 11 time points spread over 24 hours after injection. The ex vivo analysis revealed striking pharmacodynamic and pharmacokinetic differences between the three heparins. UFH had the lowest bioavailability regarding the aPTT, aXa, and aIIa activities. Enoxaparin exhibited only low aIIa activity but the highest aXa activity. Unlike UFH and enoxaparin, MMWH showed a high recovery of aIIa activity, which suggests that it combines the high potency to inhibit thrombin that characterizes UFH with the high bioavailability of the LMWHs. Consequently, substantially lower doses are needed to bring about effects comparable to those of UFH and LMWH.

KEYWORDS

Unfractionated heparin - medium-molecular-weight heparin - low-molecular-weight heparin - pharmacokinetics - pharmacodynamics

REFERENCES

  • 1 Hirsh J, Warkentin T E, Shaughnessy S G. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.  Chest . 2001;  119(Suppl 1) 64S-94S
    CrossrefPubMedGoogle Scholar
  • 2 Dolovich L R, Ginsberg J S, Douketis J D, Holbrook A M, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.  Arch Intern Med . 2000;  160 1881-1888
    PubMedGoogle Scholar
  • 3 Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin.  Thromb Haemost . 1994;  71 300-304
    PubMedGoogle Scholar
  • 4 Barzu T, Molho P, Tobelem G, Petitou M, Caen J. Binding and endocytosis of heparin by human endothelial cells in culture.  Biochim Biophys Acta . 1985;  845 196-203
    PubMedGoogle Scholar
  • 5 Sarret M, Kher A, Toulemonde F. Low Molecular Weight Heparin Therapy.  1st ed. New York: Marcel Dekker 1999
    Google Scholar
  • 6 Hirsh J, Weitz J I. New antithrombotic agents.  Lancet . 1999;  353 1431-1436
    CrossrefPubMedGoogle Scholar
  • 7 Weitz J I, Hirsh J. New anticoagulant drugs.  Chest . 2001;  119(Suppl 1) 39S-63S
    CrossrefPubMedGoogle Scholar
  • 8 Walenga J M, Jeske W P, Samama M M. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent.  Expert Opin Investig Drugs . 2002;  11 397-407
    CrossrefPubMedGoogle Scholar
  • 9 Shen G X. Development and current applications of thrombin-specific inhibitors. Current drug targets-cardiovascular & haematological disorders 2001;1. Available at: http://www. bentham.org/cdtchd1-1/shen/shen.htm
    Google Scholar
  • 10 Gustafsson D, Nystrom J, Carlsson S. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95. Intestinal absorption properties, biochemical and pharmacodynamic effects.  Thromb Res . 2001;  101 171-181
    CrossrefPubMedGoogle Scholar
  • 11 Lindhout T, Blezer R, Hemker H C. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma.  Thromb Haemost . 1990;  64 464-468
    PubMedGoogle Scholar
  • 12 Herault J P, Bernat A, Gaich C, Herbert M. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.  Thromb Haemost . 2002;  87 238-244
    PubMedGoogle Scholar
  • 13 Béguin S, Welzel D, Al Dieri A, Hemker H C. Conjectures and refutations on the mode of action of heparins.  Haemostasis . 1999;  29 170-188
    CrossrefPubMedGoogle Scholar
  • 14 Béguin S, Lindhout T, Hemker H C. The mode of action of heparin in plasma.  Thromb Haemost . 1988;  60 457-462
    PubMedGoogle Scholar
  • 15 Sandset P M, Abildgaard U, Larsen M L. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI).  Thromb Res . 1988;  50 803-813
    CrossrefPubMedGoogle Scholar
  • 16 Abildgaard U, Lindahl A K, Sandset P M. Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood.  Haemostasis . 1991;  21 254-257
    PubMedGoogle Scholar
  • 17 Valentin S, Ostergaard P, Kristensen H, Nordfang O. Synergism between full length TFPI and heparin: evidence for TFPI as an important factor for the antithrombotic activity of heparin [letter].  Blood Coagul Fibrinolysis . 1992;  3 221-222
    PubMedGoogle Scholar
  • 18 Abildgaard U. Heparin/low molecular weight heparin and tissue factor pathway inhibitor.  Haemostasis . 1993;  23(Suppl 1) 103-106
    PubMedGoogle Scholar
  • 19 Linhardt R J, Toida T. Heparin oligosaccharides: new analogues development and applications. In: Witczak ZJ, Nieforth KA, eds. Carbohydrates in Drug Design New York: Marcel Dekker 1997: 277-341
    Google Scholar
  • 20 Zacharski L R, Ornstein D L. Heparin and cancer.  Thromb Haemost . 1998;  17 289-297
    PubMedGoogle Scholar
  • 21 Linhardt R J, Loganathan D, al-Hakim A. Oligosaccharide mapping of low molecular weight heparins: structure and activity differences.  J Med Chem . 1990;  33 1639-1645
    CrossrefPubMedGoogle Scholar
  • 22 Choay J, Petitou M, Lormeau J C. Structure-activity relationship in heparin. A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity.  Biochem Biophys Res Commun . 1985;  128 134-140
    CrossrefPubMedGoogle Scholar
  • 23 Valentin S, Larnkjer A, Ostergaard P, Nielsen J I, Nordfang O. Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans.  Thromb Res . 1994;  75 173-183
    CrossrefPubMedGoogle Scholar
  • 24 Alban S, Gastpar R. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.  Thromb Haemost . 2001;  85 824-829
    PubMedGoogle Scholar
  • 25 Witt I, Beeser H, Müller-Berghaus G. Minimalanforderungen zur Gewinnung von Citratplasma für hämostaseologische Analysen.  Lab Med . 1995;  19 143-145
    PubMedGoogle Scholar
  • 26 Gibaldi M, Perrier D. Pharmacokinetics.  2nd ed. New York: Marcel Dekker 1992
    Google Scholar
  • 27 Rowland M, Tozer T N. Clinical Pharmacokinetics.  Concepts and Applications. Philadelphia: Lea & Febiger 1989: 459-461
    Google Scholar
  • 28 Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics.  J Pharmacokinet Biopharm . 1978;  6 547-558
    CrossrefPubMedGoogle Scholar
  • 29 Generica, Version 2.0, Prof. Dr. R. Zincke, Coesfeld, Germany, 1989 . 
    Google Scholar
  • 30 Holmer E, Mattsson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits.  Thromb Res . 1982;  25 475-485
    CrossrefPubMedGoogle Scholar
  • 31 Ockelford P A, Carter C J, Mitchell L, Hirsh J. Discordance between the anti-Xa activity and the antithrombotic activity in an ultra-low molecular weight heparin fraction.  Thromb Res . 1982;  28 401-409
    CrossrefPubMedGoogle Scholar
  • 32 Thomas D P, Merton R E, Barrowcliffe T W, Thunberg L, Lindahl U. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.  Thromb Haemost . 1982;  47 244-248
    PubMedGoogle Scholar
  • 33 Bergqvist D, Nilsson B, Hedner U, Pedersen P C, Ostergaard P B. The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis.  Thromb Res . 1985;  38 589-601
    CrossrefPubMedGoogle Scholar
  • 34 Thomas D P, Merton R E, Gray E, Barrowcliffe T W. The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model.  Thromb Haemost . 1989;  61 204-207
    PubMedGoogle Scholar
  • 35 Hoppensteadt D A, Jeske W, Ahsan A, Walenga J M, Fareed J. Biochemical and pharmacologic profile of defined molecular weight fractions of heparin.  Semin Thromb Hemost . 1993;  19 12-19
    PubMedGoogle Scholar
  • 36 Samama M M, Bara L, Gerotziafas G T. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs).  Haemostasis . 1994;  24 105-117
    PubMedGoogle Scholar
  • 37 Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirements for a carbohydrate based anticoagulant with reduced risk of inducing the immunological type of heparin-associated thrombocytopenia.  Thromb Haemost . 1995;  74 886-892
    PubMedGoogle Scholar
  • 38 Warkentin T E, Levine M N, Hirsh J. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin.  N Engl J Med . 1995;  332 1330-1335
    CrossrefPubMedGoogle Scholar
  • 39 Ockelford P A, Carter C J, Cerskus A, Smith C A, Hirsh J. Comparison of the in vivo hemorrhagic and antithrombotic effects of a low antithrombin-III affinity heparin fraction.  Thromb Res . 1982;  27 679-690
    CrossrefPubMedGoogle Scholar
  • 40 Cade J F, Buchanan M R, Boneu B. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation.  Thromb Res . 1984;  35 613-625
    CrossrefPubMedGoogle Scholar
      >